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substantial: it is estimated that in 2012, 1.2 million HIV-related
deaths occurred. These deaths are chieﬂy related to tuberculosis
(TB) and opportunistic infections, particularly cryptococcal menin-
gitis. Post-mortem data from Africa demonstrates that 30-50% of
HIV-related deaths have active TB disease, and in many cases the
TB was undiagnosed ante-mortem. Under-diagnosis and late diag-
nosis of TB in HIV is a major driver of mortality and related to
non-speciﬁc clinical presentations, poor sensitivity of available
diagnostics, frequent extra-pulmonary involvement and rapidity
of clinic deterioration in patients with severe immunodeﬁciency.
In hospitalised patients diagnosed with TB case fatality rates are
particularly high (11-50%), despite TB treatment, ART and co-
trimoxazole prophylaxis and reasons for this need to be further
examined to improve acute management strategies and outcomes.
The contribution of bacterial infections to HIV-TB deaths needs to
be more accurately deﬁned. Mortality rates in patients started on
ART in Africa are higher than in industrialised countries even after
adjusting for CD4 count. Studies of routine screening, regardless
of symptoms, amongst patients commencing ART in Africa have
demonstrated high prevalence of active TB (up to 25%) and crypto-
coccal antigenaemia (up to 20% in thosewith CD4<100) suggesting
such routine screening should be considered where resources per-
mit and may impact mortality. However, outcomes data on the
impact of such screeningprogrammes is limited.Health systemand
patient factors contribute to ongoing mortality: many patients are
only diagnosed with HIV when immunosuppression is advanced,
in a subset of patients adherence on ART is poor resulting in viro-
logical failure and default from the ART programme is associated
with substantial morbidity. The net result is that there remains a
signiﬁcant population of HIV-infected people with low CD4 counts
amongst whom mortality remains high.
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Investment in healthcare in Africa has increased signiﬁcantly
over the past decade driven by efforts to combat HIV, TB, malaria
as well as in response to Africa’s development trends and new
health priorities. Unfortunately, medical laboratories in Africa are
unfortunately under-developed and suffer from both systemic and
infrastructure capacity weaknesses. They cannot meet the testing
demands of rapidly growing health delivery services on the conti-
nent.
The African Society for Laboratory Medicine, a pan-African
professional body endorsed by the Africa Union, is focused on
improving healthcare by improving laboratory services. In 2012,
ASLM convened its inaugural conference themed “Accurate diag-
nostics is the Cornerstone of Quality Healthcare”. At this meeting,
six AfricanMinisters of Health signed a Call to Action for Laboratory
Strengthening in Africa. This statement recognized that laboratory
tests arepivotal in disease diagnosis, patient management, surveil-
lance, outbreak investigation, and research and highlighted the
integral link between expanded access to high quality, reliable lab-
oratory services and improved health outcomes.
Recognizing the 2008 WHO Resolution AFR/RC58/R2 for
strengthening public health laboratories in the African region,
ASLM is advancing the Call to Action by working collaboratively
with governments, regional and international organizations, and
the private sector towards the following goals by 2020 – (i)
strengthening the laboratory workforce through training and
retention initiatives; (ii) accrediting laboratories to improve testing
quality and reliability; (iii) developing strong, harmonized regula-
tory systems for diagnostic products to improve patient safety and;
(iv) building a network of public health reference laboratories to
improve early disease detection and south-south collaboration.
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Antibiotic use and the trends of gram-negative
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Bacterial resistance in clinically important pathogens has
reached alarming rates and exerts a signiﬁcant impact on clinical
outcomes. This phenomenon is longer conﬁned to the hospi-
tal setting alone and will continue to worsen if not addressed,
due to the fact that no antimicrobial options for severe Gram-
negative bacterial infections (GNB) are on the immediate horizon.
The speciﬁc multidrug (MDR), extensive drug (XDR) and pan-
drug resistant (PDR) bacteria that necessitate, antimicrobial
stewardship (AMS) or antibiotic conservation as a matter of
urgency, are the extended-spectrum -lactamase (ESBL) produc-
ing and/or carbapenemase-producing Enterobacteriaceae (CPE)
(e.g. Escherichia coli and Klebsiella pneumonia). Indeed, col-
istin resistance amongst the latter pathogens have now emerged
amongst the major carbapenemase genotypes (e.g NDM, KPC and
OXA-48-like) and have been described from several continents.
Regarding carbapenemases, several studies have shown that prior
carbapenem therapy is not a prerequisite for acquisition of CPE.
The genes conferring such resistance usually reside on large plas-
mids, which frequently carry additional resistance determinants
that confer cross-resistance to several if not all antibiotic classes.
As a consequence, prior use of any antibiotic may select for
carbapenemase-producing GNB. Besides the XDR nature of the CPE
genes, the role of formulary interventions in controlling CPE is not
well studied. Therefore, rather than targeting a speciﬁc class or
limiting speciﬁc agents, an overall reduction in antibiotic use is
recommended as a focus for ASPs. A patient’s cumulative antibi-
otic exposure history is likely to be more important than any one
speciﬁc exposure when determining the likelihood of developing
a CPE infection. It also appears that not only is prior cumulative
exposure a risk factor, but that the risk increases with increasing
duration of prior treatment. Hence, the development of resistance
is a complex consequence of inappropriate prior antibiotic use
which include homogenous and repetitive use (always the same
agent), excessiveuse (e.g. routine combination therapy), prescribed
